Mallinckrodt, Premier broaden agreement

Article

Mallinckrodt has expanded its agreement with group purchasing organization Premier, adding new products and extending their existing contract by two years. New Mallinckrodt technologies and products added to the partnership include Nellcor pulse

Mallinckrodt has expanded its agreement with group purchasing organization Premier, adding new products and extending their existing contract by two years. New Mallinckrodt technologies and products added to the partnership include Nellcor pulse oximeters and sensors, Liebel-Flarsheim power injector disposables, and the Optison ultrasound contrast agent (developed by San Diego-based Molecular Biosystems).

The earlier agreement between Premier and Mallinckrodt covered other Mallinckrodt contrast imaging agents, radiopharmaceuticals and related products, endotracheal tubes, tracheostomy tubes, and temperature monitoring systems. All of those items will remain under the new expanded agreement, which will conclude at the end of 2006, according to St. Louis-based Mallinckrodt.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.